Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | MicrobiomeTrials← Back to trialsNCT05747924
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
CompletedPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-04-04Est. Completion: 2026-03-18
Enrollment target: 90 participants Locations- University of California Los Angeles, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- University of California San Diego, San Diego, California, United States
- University of Colorado, Denver, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- Rare Disease Research, Atlanta, Georgia, United States
- Kansas University Medical Center, Kansas City, Kansas, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Duke University, Durham, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Texas Southwestern, Dallas, Texas, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- University of Washington, Seattle, Washington, United States
- University of Ottawa, Ottawa, Ontario, Canada
- University College London, London, United Kingdom
Other microbiome trials you might be interested in
Facioscapulohumeral Muscular DystrophyFSHDFSHD - Facioscapulohumeral Muscular DystrophyFSHD1FSHD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Facioscapulohumeral Muscular Dystrophy 1Facioscapulohumeral DystrophyFacio-Scapulo-Humeral DystrophyFacioscapulohumeral Muscular Dystrophy 2Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)FSH Muscular DystrophyLandouzy Dejerine DystrophyLandouzy-Dejerine Muscular Dystrophy
University of Sheffield, Sheffield, United KingdomLandouzy-Dejerine Syndrome
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 102…
Orange, United StatesEst. completion May 2028
Facioscapulohumeral Muscular Dystrophy
The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is…
Los Angeles, United StatesEst. completion Jul 7, 2027